Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus

Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., Kallenberg, C. G. M. · 1990 · Arthritis & Rheumatism

Abstract

To evaluate the predictive power of changes in levels of antibodies to double‐stranded DNA (anti‐dsDNA) as a predictor of disease exacerbations in systemic lupus erythematosus (SLE), we performed a prospective study on 72 unselected patients with SLE (mean duration of study 18.5 months, range 6–35 months). Patients were seen at least once every 3 months, and disease activity was scored according to a specific protocol. Plasma samples were obtained at least once every month and were assessed for anti‐dsDNA antibody (by the Crithidia luciliae assay, an enzymelinked immunosorbent assay [ELISA], and the Farr assay) and for complement components C3 and C4. Twenty‐seven of 33 disease exacerbations observed during the study period were accompanied by a positive test result for anti‐dsDNA antibody (27 by the Farr assay, 19 by the C luciliae assay, and 23 by the ELISA). Twenty‐four of these exacerbations were preceded by a significant increase in anti‐dsDNA antibody levels (23 by the Farr assay, 12 by the C luciliae assay, and 17 by the ELISA). The first observance of a significant increase in anti‐dsDNA antibody levels preceded the exacerbation by 8–10 weeks. Significant increases in anti‐dsDNA antibody levels not followed by an exacerbation were observed in 5 cases by the Farr assay, in 7 cases by the C luciliae assay, and in 3 cases by the ELISA; however, in 3 cases, 2 cases, and 1 case, respectively, these increases were followed by an increase in disease activity that did not fulfill the criteria for an exacerbation. Serial measurement of anti‐dsDNA antibody levels was more sensitive for predicting exacerbations than was measurement of C3 and/or C4 levels ( P < 0.03). Serial assessment of anti‐dsDNA antibody levels, especially by the Farr assay, is a sensitive and reasonably specific method for predicting disease exacerbations in SLE.

Overview

Integrity signals

Registry

Crossref · 10.1002/art.1780330505

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. Wallace DJ, 1987, Lupus Erythematosus
  2. Cameron JS, 1976, Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations., Clin Exp Immunol, 25, 418

Cited by

See all 579

Metadata

Authors
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M.
Affiliations
University Medical Center Groningen (NL)
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
1990-05
Volume
33
Issue
5
Pages
634-643
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2113059823
Cited by
572
References
34
Citations by year
2026: 7 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 14 · 2018: 16 · 2017: 14 · 2016: 15 · 2015: 24 · 2014: 27 · 2013: 24 · 2012: 22
FWCI
11.54
Type
journal article
Language
en
Open access
closed
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
systemic lupus erythematosus, anti-dsDNA antibodies, disease exacerbation, disease activity prediction, complement C3, complement C4, Farr assay, ELISA
MeSH terms
Adolescent, Adult, Aged, Antibodies, Antinuclear, Complement C3, Complement C4, DNA, Enzyme-Linked Immunosorbent Assay, Female, Forecasting, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. https://app.cochat.ai/papers/10.1002/art.1780330505
The paper
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990). Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis & Rheumatism. https://doi.org/10.1002/art.1780330505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.